Scionxbio
Founded 2026 · 17 employees on LinkedIn · 1 known investors
ScionX develops xRNA, an engineered RNA platform that uses site-specific chemical modifications and expanded non-natural building blocks to extend protein expression from days to months and deliver multiple coordinated payloads against several disease drivers. It applies a deep-learning design engine and combinatorial chemical synthesis to build long-acting RNA therapeutics, initially focused on cardiometabolic and other chronic diseases.
Investors · 1
Frequently asked questions
- What does Scionxbio do?
- ScionX develops xRNA, an engineered RNA platform that uses site-specific chemical modifications and expanded non-natural building blocks to extend protein expression from days to months and deliver multiple coordinated payloads against several disease drivers. It applies a deep-learning design engine and combinatorial chemical synthesis to build long-acting RNA therapeutics, initially focused on cardiometabolic and other chronic diseases.
- Who are Scionxbio's investors?
- Scionxbio's investors include Kindred Capital.